MiNA & Nippon Shinyaku have entered into a research collaboration & licensing agreement under which MiNA will identify RNAa candidates by employing its RNAa algorithm and technology platform as a treatment of rare neurodegenerative disorders
Nippon Shinyaku gains an option to exclusively license the therapeutic candidates supported by the early-stage preclinical data to further carry out their research, development & commercialization activities
MiNA will receive an undisclosed upfront payment and development milestones for the RNAa candidates. If Nippon Shinyaku exercises its exclusive option, it will get the payment for development and commercialization, milestones plus sales-based royalties post-product launch
Ref: MiNA Therapeutics | Image: MiNA Therapeutics
Related Post:- EIP Pharma Entered into a Definitive Merger Agreement with Diffusion Pharmaceuticals to Advance Neflamapimod for Neurodegenerative Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
